Ann: Achievement of key stem cell manufacturing milestone, page-10

ABC tabloid beat up swallowed whole by AUS mkt.
But RGS Q1-3 '14 needed mgmt. shakeup & definitive demonstration of value & efficacy. Fluffy marketing = target. Young chuffed small bio, not the first to err.
ABC and mkt provided needed external bashing, co. responded & much better for it. Q1-15 SP much undervalued.
If solid partnerships + efficacy demonstrated, ABC hangover will pass and .12-.18 = sub-basement.
Mkt wary of fluffy announcements from this co. But this = positive sign. Q1&2-15 important to definitively demonstrate value. Good start.